Triana Biomedicines, Inc.

Who: Roche’s Genentech/Orionis Biosciences What: The companies signed a second deal focused on molecular glue drugs in oncology. Why: The deal expands on an existing partnership between Orionis

AbbVie, Biogen, Pfizer and Novartis have each signed collaborations with biotechs centered on molecular glue degradation in fields such as cancer, immunology and neurology in just the past five months

Who : AbbVie and Neomorph What: The two companies have signed a collaboration and option-to-license deal to develop molecular glue degraders in oncology and immunology. Why: The deal brings togeth

Who: Pfizer/Triana Biomedicines What: Pfizer is partnering with Triana to discover novel molecular glue degraders for multiple targets in several disease areas. Why: Pfizer becomes the latest big